Anixa Biosciences (ANIX) Enterprise Value (2010 - 2026)
Anixa Biosciences' (ANIX) quarterly Enterprise Value came in at -$27.1 million in Q2 2026, down 61.98% YoY from -$71.4 million in Q2 2025, and up 10.45% on a QoQ basis from -$30.3 million in Q4 2025.
Anixa Biosciences (ANIX) Enterprise Value (2010 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 17 years of Enterprise Value data on file, last reported at -$27.1 million in Q2 2026.
- Quarterly Enterprise Value fell 61.98% year-over-year to -$27.1 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was -$27.1 million (down 61.98% YoY) and the FY2025 annual result came in at -$30.3 million, up 23.69% from the prior year.
- Enterprise Value rose to -$27.1 million in Q2 2026, from -$30.3 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$16.8 million in Q2 2025 to a low of -$49.1 million in Q2 2023.
- A 5-year average of -$35.5 million and a median of -$35.3 million in 2022 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value plunged 143.04% — and 2025, when it soared 63.87%.
- Tracing ANIX's Enterprise Value over 5 years: stood at -$47.7 million in 2022, then advanced by 0.16% to -$47.6 million in 2023, then increased by 16.55% to -$39.7 million in 2024, then climbed by 23.69% to -$30.3 million in 2025, then grew by 10.45% to -$27.1 million in 2026.
- The last three Enterprise Value figures came in at -$27.1 million (Q2 2026), -$30.3 million (Q4 2025), and -$17.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 2.12 Bn |
| 10 | Anixa Biosciences | 125.30 Mn | 125.30 Mn | - | -27.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -27.15 Mn |
| Oct 31, 2025 | -30.32 Mn |
| Jul 31, 2025 | -17.21 Mn |
| Apr 30, 2025 | -16.76 Mn |
| Jan 31, 2025 | -18.39 Mn |
| Oct 31, 2024 | -39.73 Mn |
| Jul 31, 2024 | -41.35 Mn |
| Apr 30, 2024 | -46.38 Mn |
| Jan 31, 2024 | -43.62 Mn |
| Oct 31, 2023 | -47.60 Mn |
| Jul 31, 2023 | -48.66 Mn |
| Apr 30, 2023 | -49.08 Mn |
| Jan 31, 2023 | -28.58 Mn |
| Oct 31, 2022 | -47.68 Mn |
| Jul 31, 2022 | -32.46 Mn |
| Apr 30, 2022 | -33.00 Mn |
| Jan 31, 2022 | -35.25 Mn |
| Oct 31, 2021 | -36.40 Mn |
| Jul 31, 2021 | -37.23 Mn |
| Apr 30, 2021 | -38.66 Mn |